Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 5/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.38 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.38 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.38 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11627661 | 0.94 | KIF11 (0.50) | PDE2AKIF11AKR1C3AKR1C2 | |
| SCHEMBL15442613 | 0.81 | MAOB (0.62) | — | |
| SCHEMBL1046560 | 0.81 | PDE2A (0.50) | PDE2ACES2CES1ALDH1A1ACP3 | |
| SCHEMBL84043 | 0.80 | PDE2A (0.53) | PDE2ACES2CES1ALDH1A1ACP3 | |
| SCHEMBL6564267 | 0.80 | CES2 (0.45) | PDE2ACES2CES1ALDH1A1ACP3 | |
| SCHEMBL6075652 | 0.80 | CES2 (0.45) | PDE2ACES2CES1ALDH1A1ACP3 | |
| SCHEMBL2865480 | 0.79 | ADRB2 (0.41) | ALDH1A1TSHR | |
| SCHEMBL7438101 | 0.78 | PDE2A (0.52) | PDE2ACES2CES1ALDH1A1ACP3 | |
| Ammonia Solution, Strong SCHEMBL27642816 | 0.78 | PDE2A (0.52) | PDE2ACES2CES1ALDH1A1ACP3 | |
| SCHEMBL8955877 | 0.78 | TSHR (0.46) | PDE2AALDH1A1TSHRKIF11AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492172-B2 | Substituted quinazolinyl compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4021901-B1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4081516-B1 | SUBSTITUTED QUINAZOLINYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4583876-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | Juno Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-120152717-A | Combination of T cell therapy and continuous or intermittent DGK inhibitor administration | 朱诺治疗学股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250179017-A1 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| CN-119487006-A | Amide compounds as PGE2 receptor antagonists | 广东新契生物医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4482824-A1 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | Guangdong Newopp Biopharmaceuticals Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-05 | — | — | US | disclosed |
| CN-114846007-B | Substituted quinazolinyl compounds useful as T cell activators | 百时美施贵宝公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-1595894-A1 | PROCESS FOR THE PRODUCTION OF LIVING RADICAL POLYMERS AND POLYMERS | OTSUKA CHEMICAL COMPANY, LIMITED (JP) | 2005-11-16 | — | — | EP | disclosed |
| US-20050245714-A1 | Organic tellurium compound, process for producing the same, living radical polymerization initiator, process for producing polymer with the same, and polymer | OTSUKA CHEMICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| CN-1675253-A | Method for producing living radical polymer and polymer | OTSUKA CHEMICAL CO LTD (JP) | 2005-09-28 | — | — | CN | disclosed |
| CN-1649838-A | Organic tellurium compound, method for producing same, living radical polymerization initiator, method for producing polymer using same, and polymer | OTSUKA KAGAKU KK (JP) | 2005-08-03 | — | — | CN | disclosed |
| EP-1541550-A1 | ORGANIC TELLURIUM COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER WITH THE SAME, AND POLYMER | Otsuka Chemical Co., Ltd. (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1541592-A1 | PROCESS FOR PRODUCTION OF LIVING RADICAL POLYMERS AND POLYMERS | OTSUKA CHEMICAL COMPANY, LIMITED (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-4081596-A | DIURETIC, SALURETIC, ANTIHYPERTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-28 | — | — | US | disclosed |
| US-4005215-A | DIURETIC | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-25 | — | — | US | disclosed |
| US-3978077-A | DIURETIC, HYPOTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (GB) | 1976-08-31 | — | — | US | disclosed |
| US-3957814-A | DIURETICS, SALURETICS, HYPOTENSIVE AGENTS, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245714-A1 | Organic tellurium compound, process for producing the same, living radical polymerization initiator, process for producing polymer with the same, and polymer | ODC1, TERB1, TTI1 | PDE2A 3867/4885CES2 900/4885CES1 1061/4885 |
| US-20250179017-A1 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | PTGER1, PTGER2, CNR2 | PDE2A 336/4885CES2 761/4885CES1 429/4885 |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | PDE2A 1693/4885CES2 4254/4885CES1 3187/4885 |
| US-12492172-B2 | Substituted quinazolinyl compounds useful as T cell activators | DGKZ, DGKA, DGKK | PDE2A 1660/4885CES2 3720/4885CES1 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.